Kyntra Bio Inc (NASDAQ:KYNB) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $32.50.

Several equities analysts have recently issued reports on KYNB shares. Wall Street Zen raised shares of Kyntra Bio from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th. Oppenheimer initiated coverage on Kyntra Bio in a report on Monday, July 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Rodman & Renshaw assumed coverage on Kyntra Bio in a report on Tuesday, June 9th. They set a “buy” rating and a $30.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Kyntra Bio in a research note on Tuesday, June 16th.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC purchased a new position in Kyntra Bio Inc (NASDAQ:KYNB) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned 0.26% of Kyntra Bio as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 72.71% of the company’s stock.

Kyntra Bio Trading Up 0.1%

Shares of NASDAQ KYNB opened at $6.79 on Friday. The firm has a 50 day simple moving average of $7.07. Kyntra Bio has a 1 year low of $6.32 and a 1 year high of $12.60. The company has a market cap of $27.50 million, a price-to-earnings ratio of 0.17 and a beta of 0.96.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.